scholarly journals Insulin like growth factor 2 regulation of aryl hydrocarbon receptor in MCF-7 breast cancer cells

2014 ◽  
Vol 443 (3) ◽  
pp. 1092-1096 ◽  
Author(s):  
Justin K. Tomblin ◽  
Travis B. Salisbury
Keyword(s):  
Breast Cancer ◽  
Growth Factor ◽  
Aryl Hydrocarbon Receptor ◽  
Cancer Cells ◽  
Breast Cancer Cells ◽  
Insulin Like Growth Factor ◽  
Aryl Hydrocarbon ◽  
Mcf 7

scholarly journals The Role of Aryl Hydrocarbon Receptor and Crosstalk with Estrogen Receptor in Response of Breast Cancer Cells to the Novel Antitumor Agents Benzothiazoles and Aminoflavone

2011 ◽  
Vol 2011 ◽  
pp. 1-9 ◽  
Author(s):  
Mariana A. Callero ◽  
Andrea I. Loaiza-Pérez
Keyword(s):  
Breast Cancer ◽  
Estrogen Receptor ◽  
Aryl Hydrocarbon Receptor ◽  
Cancer Cells ◽  
Breast Cancer Cells ◽  
Antitumor Agents ◽  
Breast Cancers ◽  
Nude Mouse Model ◽  
Aryl Hydrocarbon ◽  
Mcf 7

Many estrogen-receptor- (ER-) expressing breast cancers become refractory to ER-based therapies. New antitumor drugs like aminoflavone (AF) and benzothiazoles (Bzs) have been developed and have exquisite antitumor activity in ER+MCF-7 and T47D cells and in a MCF-7 nude mouse model. ER(−) breast cancer cells like MDA-MB-231 are less susceptible. We previously found in MCF-7 cells that these drugs activate the aryl hydrocarbon receptor (AhR) via translocation to the nucleus, induction of AhR-specific DNA binding activity, and expression of CYP1A1, whose transcription is controlled by the AhR-ARNT transcription factor. CYP1A1 metabolizes AF and Bz to a species which directly or after further metabolism damages DNA. In contrast an AhR-deficient variant of MCF-7 or cells with predominantly nuclear AhR expression, such as MDA-MB 231, are resistant. Thus, these drugs, unlike other neoplastic agents, require AhR-mediated signaling to cause DNA damage. This is a new treatment strategy for breast cancers with intact AhR signaling.

scholarly journals Affinity for the insulin-like growth factor-II (IGF-II) receptor inhibits autocrine IGF-II activity in MCF-7 breast cancer cells.

1996 ◽  
Vol 10 (3) ◽  
pp. 286-297 ◽  
Author(s):  
M J Ellis ◽  
B A Leav ◽  
Z Yang ◽  
A Rasmussen ◽  
A Pearce ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Growth Factor ◽  
Cancer Cells ◽  
Breast Cancer Cells ◽  
Insulin Like Growth Factor ◽  
Factor Ii ◽  
Mcf 7

scholarly journals Berberine Activates Aryl Hydrocarbon Receptor but Suppresses CYP1A1 Induction through miR-21-3p Stimulation in MCF-7 Breast Cancer Cells

Molecules ◽  
2017 ◽  
Vol 22 (11) ◽  
pp. 1847 ◽  
Author(s):  
Sheng-Nan Lo ◽  
Chun-Wei Wang ◽  
Yueh-Shieh Chen ◽  
Chiung-Chiao Huang ◽  
Tian-Shung Wu ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Aryl Hydrocarbon Receptor ◽  
Cancer Cells ◽  
Breast Cancer Cells ◽  
Aryl Hydrocarbon ◽  
Cyp1a1 Induction ◽  
Mcf 7

Conditional expression of a constitutively active aryl hydrocarbon receptor in MCF-7 human breast cancer cells

2002 ◽  
Vol 402 (2) ◽  
pp. 172-179 ◽  
Author(s):  
Christoph Köhle ◽  
Ingo Hassepass ◽  
Barbara S Bock-Hennig ◽  
Karl Walter Bock ◽  
Lorenz Poellinger ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Aryl Hydrocarbon Receptor ◽  
Cancer Cells ◽  
Human Breast Cancer ◽  
Breast Cancer Cells ◽  
Human Breast Cancer Cells ◽  
Human Breast ◽  
Aryl Hydrocarbon ◽  
Conditional Expression ◽  
Mcf 7

INSULIN-LIKE GROWTH FACTOR TYPE I AND INSULIN-LIKE GROWTH FACTOR TYPE II STIMULATE OESTRADIOL-17β HYDROXYSTEROID DEHYDROGENASE (REDUCTIVE) ACTIVITY IN BREAST CANCER CELLS

1991 ◽  
Vol 129 (2) ◽  
pp. R5-R8 ◽  
Author(s):  
Anita Singh ◽  
M.J. Reed
Keyword(s):  
Breast Cancer ◽  
Growth Factor ◽  
Cancer Cells ◽  
Breast Cancer Cells ◽  
Hydroxysteroid Dehydrogenase ◽  
Type I ◽  
Insulin Like Growth Factor ◽  
Igf I ◽  
Factor Type ◽  
Mcf 7

ABSTRACT Oestradiol-17β hydroxysteroid dehydrogenase (E2DH) is present in normal and malignant breast tissues and also in cultured breast cancer cells. It can act in a reductive direction to convert oestrone to the biologically active oestrogen, oestradiol, or in an oxidative direction to metabolize oestradiol to oestrone and may therefore have a crucial role in regulating breast tissue concentrations of oestradiol. Insulin-like growth factor-type I (IGF-I) and IGF-II are both mitogens for breast cancer cells. In this study we have examined the effect of these growth factors on the reductive and oxidative activities of E2DH in MCF-7 (receptor positive) and MDA-MB-231 (receptor negative) breast cancer cells. Both IGF-I (80 ng/ml) and IGF-II (80 ng/ml) significantly stimulated E2DH reductive activity (up to 138%) in MCF-7 cells but had no effect on oxidative activity. Addition of IGF-II (100 ng/ml) to MDA-MB-231 cells resulted in a small but statistically significant (p<0.05) increase in E2DH reductive activity (18%) but in these cells reductive activity is 25-70 times lower than oxidative activity. If IGF-I and IGF-II act to stimulate E2DH reductive activity in breast tumours then such a mechanism could account for the increased concentrations of oestradiol detected in breast tumours.

Sign in / Sign up

Export Citation Format

Share Document